A novel placebo lead-in behavior strategy for sertraline dosing in a depressed patient highly sensitive to medication side effects.
Moss
J H
JH
D015057:1-Naphthylamine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D000928:Antidepressive Agents / Q000009:adverse effects; D003131:Combined Modality Therapy; D003866:Depressive Disorder / Q000188:drug therapy*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008875:Middle Aged; D010349:Patient Compliance; D010919:Placebos / Q000008:administration & dosage*; D011613:Psychotherapy; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D020280:Sertraline
D015057:1-Naphthylamine; D000928:Antidepressive Agents; D010919:Placebos; D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline